Rheumatology

Top Medical News
3 days ago
Patients with colchicine-resistant familial Mediterranean fever benefit from long-term treatment with canakinumab, preventing flares and controlling disease activity without increasing adverse events, according to the results of a phase III study.
Elvira Manzano, 5 days ago
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
6 days ago
Several serum biomarkers of disease activity have been recognized in giant cell arteritis (GCA) and eosinophilic granulomatosis with polyangiitis (EGPA), according to a study. Moreover, differences in biomarker levels between diseases are more evident than those related to disease activity.
Jairia Dela Cruz, 6 days ago
The Janus kinase inhibitors tofacitinib 10 mg and peficitinib 150 mg prove to be the most effective regimens in the treatment of patients with refractory rheumatoid arthritis (RA) receiving methotrexate (MTX), without increasing the risk of serious adverse events, according to the results of a network meta-analysis.
31 Jul 2020
Extended treatment with transcranial direct current stimulation applied over dorsolateral prefrontal cortex induces large reductions in pain in fibromyalgia patients, as shown in a study.
30 Jul 2020
A strategy of administering abaloparatide for 18 months followed by 24 months of alendronate holds fracture risk at bay in older postmenopausal women with osteoporosis, as shown in a study.
Audrey Abella, 29 Jul 2020
Balneotherapy and peloid therapy demonstrated efficacy in reducing pain and improving function in patients with knee osteoarthritis (OA) as opposed to physical therapy (PT) alone, a study has shown.
Conference Reports
Elvira Manzano, 05 Aug 2020
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
Audrey Abella, 21 Jul 2020
The IL-1 receptor antagonist anakinra – a drug for rheumatoid arthritis – demonstrated potential in treating gout, as it reduced gout pain and flares to similar degrees as triamcinolone, results of the ANAGO* study have shown.
Pearl Toh, 20 Jul 2020
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
Audrey Abella, 20 Jul 2020
Use of the monoclonal antibody ixekizumab led to improvements in symptoms, work productivity, and overall functioning and health in patients with nonradiographic axial spondyloarthritis (nr-axSpA), subgroup results of the phase III COAST-X trial have shown.
Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Elaine Soliven, 15 Jul 2020
 Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
Audrey Abella, 09 Jul 2020
The anti-interleukin 17A antibody netakimab reduces disease activity and skin manifestations in patients with active psoriatic arthritis (PsA), consequently improving patient-reported outcomes (PROs), analyses of the phase III PATERA trial have shown.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download